Insider Transactions in Q1 2024 at Alkermes Plc. (ALKS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,308
-0.48%
|
$41,856
$32.18 P/Share
|
|
Feb 18
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,448
+1.6%
|
-
|
|
Feb 18
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,869
-1.21%
|
$59,808
$32.18 P/Share
|
|
Feb 18
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
6,355
+3.96%
|
-
|
|
Feb 18
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,951
-4.08%
|
$126,432
$32.18 P/Share
|
|
Feb 18
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,897
+8.41%
|
-
|
|
Feb 18
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,869
-1.73%
|
$59,808
$32.18 P/Share
|
|
Feb 18
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,355
+5.55%
|
-
|
|
Feb 15
2024
|
Cato T Laurencin Director |
SELL
Open market or private sale
|
Direct |
2,690
-15.06%
|
$83,390
$31.85 P/Share
|
|
Feb 15
2024
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,690
+13.09%
|
$59,180
$22.52 P/Share
|
|
Feb 10
2024
|
Brian P Mckeon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,088
-4.49%
|
$29,376
$27.32 P/Share
|
|
Feb 10
2024
|
Brian P Mckeon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,533
+15.76%
|
-
|
|
Feb 10
2024
|
David Angelo Daglio Jr. Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,088
-4.49%
|
$29,376
$27.32 P/Share
|
|
Feb 10
2024
|
David Angelo Daglio Jr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,533
+15.76%
|
-
|
|
Feb 08
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,007
-7.29%
|
$286,182
$26.77 P/Share
|
|
Feb 08
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,835
+19.62%
|
-
|
|
Feb 08
2024
|
Richard F Pops Director and CEO, Alkermes plc |
SELL
Payment of exercise price or tax liability
|
Direct |
91,757
-7.22%
|
$2,385,682
$26.77 P/Share
|
|
Feb 08
2024
|
Richard F Pops Director and CEO, Alkermes plc |
BUY
Grant, award, or other acquisition
|
Direct |
218,551
+14.67%
|
-
|
|
Feb 08
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,137
-7.41%
|
$211,562
$26.77 P/Share
|
|
Feb 08
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,012
+19.74%
|
-
|
|
Feb 08
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
8,483
-5.43%
|
$220,558
$26.77 P/Share
|
|
Feb 08
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
28,240
+15.31%
|
-
|
|
Feb 08
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,280
-14.8%
|
$397,280
$26.77 P/Share
|
|
Feb 08
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,658
+31.13%
|
-
|
|
Feb 08
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,183
-1.17%
|
$82,758
$26.77 P/Share
|
|
Feb 08
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
21,485
+7.32%
|
-
|
|
Feb 08
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,135
-11.63%
|
$211,510
$26.77 P/Share
|
|
Feb 08
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,012
+27.86%
|
-
|